<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bone Res</journal-id><journal-id journal-id-type="iso-abbrev">Bone Res</journal-id><journal-title-group><journal-title>Bone Research</journal-title></journal-title-group><issn pub-type="ppub">2095-4700</issn><issn pub-type="epub">2095-6231</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27088043</article-id><article-id pub-id-type="pmc">4820739</article-id><article-id pub-id-type="pii">boneres20165</article-id><article-id pub-id-type="doi">10.1038/boneres.2016.5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The biological function of type I receptors of bone morphogenetic protein in bone</article-title><alt-title alt-title-type="running">Biological function of BMPRI in bone</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Shuxian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Svoboda</surname><given-names>Kathy K H</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Jian Q</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Xinquan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf2">*</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Prosthodontics, Ninth People&#x02019;s Hospital Affiliated with Shanghai Jiao Tong University, School of Medicine</institution>, Shanghai, <country>China</country></aff><aff id="aff2"><label>2</label><institution>Department of Biomedical Sciences, Texas A&#x00026;M Baylor College of Dentistry</institution>, Dallas, TX, <country>USA</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>
(<email>Jfeng@bcd.tamhsc.edu</email>)</corresp><corresp id="caf2"><label>*</label>
(<email>xinquanj@aliyun.com</email>)</corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>04</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>4</volume><fpage>16005</fpage><lpage/><history><date date-type="received"><day>07</day><month>12</month><year>2015</year></date><date date-type="rev-recd"><day>04</day><month>02</month><year>2016</year></date><date date-type="accepted"><day>20</day><month>02</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Sichuan University</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Sichuan University</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><!--author-paid--><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license></permissions><abstract><p>Bone morphogenetic proteins (BMPs) have multiple roles in skeletal development, homeostasis and regeneration. BMPs signal via type I and type II serine/threonine kinase receptors (BMPRI and BMPRII). In recent decades, genetic studies in humans and mice have demonstrated that perturbations in BMP signaling via BMPRI resulted in various diseases in bone, cartilage, and muscles. In this review, we focus on all three types of BMPRI, which consist of activin-like kinase 2 (ALK2, also called type IA activin receptor), activin-like kinase 3 (ALK3, also called BMPRIA), and activin-like kinase 6 (ALK6, also called BMPRIB). The research areas covered include the current progress regarding the roles of these receptors during myogenesis, chondrogenesis, and osteogenesis. Understanding the physiological and pathological functions of these receptors at the cellular and molecular levels will advance drug development and tissue regeneration for treating musculoskeletal diseases and bone defects in the future.</p></abstract></article-meta></front><body><sec><title>Introduction</title><p>Belonging to the transforming growth factor-&#x003b2; super family,<sup><xref ref-type="bibr" rid="bib1">1</xref></sup> bone morphogenetic proteins (BMPs) were discovered and named in 1965 by Marshall Urist, who initially identified their ability to induce ectopic bones in muscles.<sup><xref ref-type="bibr" rid="bib2">2</xref></sup> In the last 50 years, the potent osteogenic activity <italic>in vitro</italic> of BMPs has been well characterized,<sup><xref ref-type="bibr" rid="bib3">3</xref></sup> as well as their constitutive activation or exogenous application, which can induce ectopic bone formation <italic>in vivo</italic>.<sup><xref ref-type="bibr" rid="bib4">4</xref>,<xref ref-type="bibr" rid="bib5">5</xref></sup> BMPs signal through cell-surface receptor complexes that consist of two distinct transmembrane serine/threonine kinase receptors, type I (BMPRI) and type II (BMPRII).<sup><xref ref-type="bibr" rid="bib6">6</xref></sup> Initially, BMP ligands bind with high affinity to BMPRI, followed by heterodimerization with BMPRII, which allows the BMPRII to phosphorylate a short stretch of amino acids in the BMPRI and activate kinase activity.<sup><xref ref-type="bibr" rid="bib6">6</xref></sup> Classically, after the activation of BMPRI, intracellular signaling is initiated through the phosphorylation of the C-terminal SSXS motif of specific receptor-regulated Smads, including Smad1, 5, and 8.<sup><xref ref-type="bibr" rid="bib7 bib8 bib9 bib10">7&#x02013;10</xref></sup> After being released from the receptor, the phosphorylated Smads form heteromeric complexes with common partner Smad, that is, Smad4. This complex is then translocated into the nucleus to regulate the transcription of genes, broadly influencing growth and differentiation.<sup><xref ref-type="bibr" rid="bib9">9</xref></sup></p><p>Three type I receptors have been shown to effectively bind BMP ligands during mammalian skeletal development&#x02014;types IA and IB BMP receptors (BMPRIA or ALK3 and BMPRIB or ALK6), as well as type IA activin receptor (ACVRI or ALK2).<sup><xref ref-type="bibr" rid="bib11">11</xref>,<xref ref-type="bibr" rid="bib12">12</xref></sup> In recent decades, studies of clinical patients, genetic animal models and cell lines have consistently demonstrated that all three type I receptors are essential for osteolineage and chondrolineage proliferation, differentiation and function. It has become clear that alterations in the intensity, location, and duration of BMPRI activity lead to heterotopic bone formation, skeleton, and cartilage deformation, as well as bone metabolism disorders. Here we provide an updated review that specifically focuses on the biological function of BMPRI in bone formation. Emphasis is placed on murine genetic studies (<xref rid="tbl1" ref-type="table">Table 1</xref>) that have assessed the requirement for and the roles of different types of BMPRI, including ALK2, ALK3, and ALK6 during osteogenesis, chondrogenesis and osteoclastogenesis, as summarized in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></sec><sec><title>Biological functions of ALK2 in bone formation</title><p>ALK2 is widely expressed in many tissues during embryonic development and is highly present in bones during postnatal development.<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> Several mesenchymal stem cell (MSC) lines show high expression levels of ALK2,<sup><xref ref-type="bibr" rid="bib11">11</xref>,<xref ref-type="bibr" rid="bib14">14</xref></sup> and its constitutive activation in myoblasts induces heterotopic bone during the endochondral bone formation process, suggesting that ALK2 has essential roles in both osteogenesis and chondrogenesis.</p><sec><title>Ectopic expression of ALK2 in myoblasts leads to heterotopic endochondral bone formation</title><p>The regulatory role of ALK2 in osteogenesis and chondrogenesis did not arouse interest until the discovery of fibrodysplasia ossificans progressiva (FOP, MIM 135100), which is characterized by congenital malformations of the great toes and progressive heterotopic ossification in muscles, tendons, ligaments, and other connective tissues.<sup><xref ref-type="bibr" rid="bib15">15</xref>,<xref ref-type="bibr" rid="bib16">16</xref></sup> Genetic analysis of FOP patients has identified gain-of-function mutations in <italic>ALK2</italic>, including c.617G&#x0003e;A (p.R206H), c.619C&#x0003e;G (p.Q207E), c.1067G&#x0003e;A (p.G356D), c.982G&#x0003e; T(p.G328W), c.983G&#x0003e; A(p.G328E), c.982G&#x0003e;A (p.G328R), c.774G&#x0003e;C/c.774G&#x0003e;T (P.R258S), c.1124G&#x0003e;C (p.R375P), c.587T&#x0003e;C (p.L196P), c.590&#x02013;592delCTT (p.P197_F198delinsL), and c.605G&#x0003e;T (p.R202I), among which R206H is the most common mutation and can be found in ~90% of FOP patients.<sup><xref ref-type="bibr" rid="bib17 bib18 bib19 bib20 bib21 bib22 bib23 bib24 bib25 bib26 bib27 bib28 bib29 bib30 bib31">17&#x02013;31</xref></sup> The classic, constitutively active ALK2 receptor containing the artificial Q207D mutation or the R206H mutation recaptures the FOP condition in transgenic animal models.<sup><xref ref-type="bibr" rid="bib32">32</xref>,<xref ref-type="bibr" rid="bib33">33</xref></sup> Further evaluation of these FOP mutations revealed that the ectopic expression of ALK2 increased Smad-dependent BMP signaling activity, which potentially occurs for both osteogenic and chondrogenic differentiation of myoblasts, thus forming heterotopic bone through an endochondral bone formation process.<sup><xref ref-type="bibr" rid="bib21">21</xref>,<xref ref-type="bibr" rid="bib32">32</xref>,<xref ref-type="bibr" rid="bib34 bib35 bib36 bib37 bib38 bib39">34&#x02013;39</xref></sup> In addition, inhibiting the activation of BMP signaling effectors Smad1/5/8 in tissues that constitutively express ALK2 resulted in a reduction of the ectopic ossification and functional impairment.<sup><xref ref-type="bibr" rid="bib32">32</xref></sup> The stable <italic>in vitro</italic> transfection of the <italic>Alk2</italic><sup><italic>R206H</italic></sup> mutation in C2C12 cells (mouse myoblasts) increased the levels of both osteogenic markers (<italic>osterix</italic> (<italic>Osx</italic>), <italic>alkaline phosphatase</italic> (<italic>Alp</italic>)) and chondrogenic markers (<italic>type II collagen</italic> (<italic>Col2</italic>), <italic>type X collagen</italic> (<italic>Col10</italic>)).<sup><xref ref-type="bibr" rid="bib40">40</xref>,<xref ref-type="bibr" rid="bib41">41</xref></sup> Conversely, knockdown of <italic>Alk2</italic> in C2C12 cells potentiated muscle differentiation and repressed BMP6-induced osteoblast differentiation.<sup><xref ref-type="bibr" rid="bib42">42</xref></sup> These elevated results suggest that Smad-dependent ALK2 signaling is important in heterotopic ossification and endochondral bone formation of myoblasts.</p></sec><sec><title>ALK2 regulates osteogenic and chondrogenic differentiation of MSCs</title><p>Studies focusing on <italic>Alk2</italic><sup><italic>R206H</italic></sup> mutant mice or cells also provide evidence indicating that ALK2 has an important role in the osteogenic differentiation of MSCs. First, the mesenchymal progenitor cells isolated from FOP (R206H) patients or <italic>Alk2</italic><sup><italic>R206H</italic></sup> mutant mice showed increased Smad-dependent BMP signaling activity with upregulated <italic>Alp</italic>, <italic>runt-related gene 2</italic> (<italic>Runx2</italic>), and <italic>osteocalcin</italic> (<italic>Ocn</italic>) genes.<sup><xref ref-type="bibr" rid="bib39">39</xref>,<xref ref-type="bibr" rid="bib43">43</xref></sup> Second, the constitutive expression of <italic>Alk2</italic> in mesenchymal cells or pre-osteoblasts makes those cells more receptive to exogenous BMPs with respect to differentiating into functional mineralizing osteoblasts.<sup><xref ref-type="bibr" rid="bib41">41</xref></sup> In contrast, specifically suppressing <italic>Alk2</italic> activity decreased the enhanced osteogenic differentiation to control levels.<sup><xref ref-type="bibr" rid="bib43">43</xref></sup> Furthermore, <italic>in vivo</italic> studies found that in heterozygous <italic>Alk2</italic><sup><italic>R206H</italic></sup> knock-in mice, the Tek/Tie2+ progenitor cells could be recruited and differentiated into bone cells in heterotopic ossification lesions.<sup><xref ref-type="bibr" rid="bib33">33</xref></sup> Consistently, a recent mouse model study showed that conditional activation of <italic>Alk2</italic> in mesodermal lineage cells resulted in ectopic bone formation at distal joints with an elevated number of osteoblast progenitors as well as bone formation activity.<sup><xref ref-type="bibr" rid="bib44">44</xref></sup> Collectively, Smad-dependent ALK2 signaling in the mesenchymal progenitors has an important role for their specification toward osteolineage cells.</p><p>In addition, the tracking study of Tek/Tie2+ progenitor cells in heterozygous <italic>Alk2</italic><sup><italic>R206H</italic></sup> knock-in mice also identified a chondrogenic differentiation of this cell population, which was responsible for forming a cartilage template that developed to form endochondral bone.<sup><xref ref-type="bibr" rid="bib33">33</xref></sup> Further analysis found that ectopic expression of <italic>Alk2</italic> increased sensitivity and accelerated chondrogenic differentiation of mouse embryonic fibroblasts and that the loss of <italic>Alk2</italic> severely inhibited chondrogenic differentiation, suggesting that ALK2 was required during early chondrogenesis.<sup><xref ref-type="bibr" rid="bib39">39</xref></sup> Moreover, studying a chick limb bud with constitutive <italic>Alk2</italic> expression showed accelerated chondrocyte maturation and induced Indian hedgehog, which is a key factor for chondrocyte maturation.<sup><xref ref-type="bibr" rid="bib45">45</xref></sup> Moreover, chondrocytes with the <italic>Alk2</italic><sup><italic>R206H</italic></sup> mutation showed increased expression of both the early chondrocyte-specific markers <italic>(sex determining region Y)-box 9</italic> (<italic>Sox9</italic>), <italic>Col2</italic>, <italic>aggrecan</italic> (<italic>Agg</italic>), and the late marker <italic>Col10</italic>.<sup><xref ref-type="bibr" rid="bib39">39</xref></sup> Collectively, these results established that ALK2 is an essential enhancer of chondrogenic differentiation.</p></sec><sec><title>Roles of ALK2 in regulating osteoblasts and osteoclasts</title><p>The endogenous expression level of <italic>Alk2</italic> in postnatal bone was found to be much higher than that in heart and skeletal muscles,<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> suggesting that ALK2 might also be essential in osteolineage cells. Accordingly, <italic>Alk2</italic> knockdown in murine osteoblast progenitors (KS483) reduced BMP6-induced osteogenic differentiation.<sup><xref ref-type="bibr" rid="bib42">42</xref></sup> Interestingly, an <italic>in vivo</italic> study found that a conditional disruption of <italic>Alk2</italic> in bone cells (including immature osteoblasts, mature osteoblasts, and osteocytes) led to an increase in endogenous bone mass during postnatal development.<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> Analysis of this mouse model indicated that the disturbed bone homeostasis was more likely due to an upregulation of canonical Wnt signaling in conjunction with the downregulation of Wnt inhibitors, scelerostin (SOST) and dickkopf 1 (DKK1; <xref ref-type="fig" rid="fig2">Figure 2</xref>).<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> In addition to BMP signaling, Wnt signaling in osteoblasts has been examined for a decade, and there is sufficient evidence supporting the hypothesis that canonical Wnt signaling serves as a bone mass inducer that positively regulates osteoblast differentiation and maturation but negatively affects osteoclast activity (see below for a detailed description).<sup><xref ref-type="bibr" rid="bib46">46</xref></sup> However, the direct regulatory role of ALK2-induced BMP signaling in late osteolineage cells remains unclear, and further evaluations need to be performed for a comprehensive understanding.</p><p>To date, no evidence has demonstrated that ALK2 directly regulates osteoclast function. However, recent studies have found that the constitutively active mutation of ALK2 in myoblasts led to the increased formation of osteoclasts from their precursors through transforming growth factor-&#x003b2; signaling. An implantation of <italic>Alk2</italic><sup><italic>R206H</italic></sup>-transfected C2C12 cells with BMP2 in nude mice resulted in robust heterotopic ossification with increased osteoclast formation in muscle tissues.<sup><xref ref-type="bibr" rid="bib47">47</xref>,<xref ref-type="bibr" rid="bib48">48</xref></sup> Furthermore, a co-culture of <italic>Alk2</italic><sup><italic>R206H</italic></sup>-transfected C2C12 cells as well as the conditioned medium from <italic>Alk2</italic><sup><italic>R206H</italic></sup>-transfected C2C12 cells enhanced osteoclast formation in mouse monocytic RAW264.7 cells.<sup><xref ref-type="bibr" rid="bib47">47</xref></sup> Mechanism analysis suggested that the elevated secretion of transforming growth factor-&#x003b2; from the mutant myoblasts led to the upregulated activation of p38 mitogen-activated protein kinase (MAPK) signaling in the surrounding monocytes, thus contributing to the enhanced osteoclastogenic differentiation.<sup><xref ref-type="bibr" rid="bib47">47</xref></sup></p></sec></sec><sec><title>Biological functions of ALK3 in bone formation</title><p>ALK3 is widely expressed in a variety of tissues during embryonic development, but it is mainly expressed in osteolineage cells and bone marrow cells during postnatal bone formation, based on <italic>in vitro</italic> studies of different cell lines.<sup><xref ref-type="bibr" rid="bib49">49</xref>,<xref ref-type="bibr" rid="bib50">50</xref></sup> Findings have confirmed a high expression level of ALK3 in osteolineage cells from MSCs to differentiated bone cells.<sup><xref ref-type="bibr" rid="bib14">14</xref>,<xref ref-type="bibr" rid="bib51 bib52 bib53 bib54">51&#x02013;54</xref></sup> Many studies have consistently indicated that ALK3 is one of the key receptors for conducting BMP signaling during osteogenesis and chondrogenesis. However, the roles of ALK3 in bone biology have remained unclear until recent studies using <italic>Alk3</italic> conditional ablation in osteogenic tissues because its conventional deletion in mice is embryonically lethal before bone development.<sup><xref ref-type="bibr" rid="bib55">55</xref></sup> It is clear that the regulatory role of ALK3 differs depending on distinctive cells, stages, tissues, and ages. ALK3-induced BMP signaling also crosstalks with the Wnt/&#x003b2;-catenin signaling pathway and functions in interactions between osteoblasts and osteoclasts.</p><sec><title>Roles of ALK3 in mesenchymal pre-osteolineage cells</title><p>In MSCs, the forced expression of <italic>Alk3</italic> (that is, the overexpression of wild-type <italic>Alk3</italic>) initiated osteogenic development. On the contrary, downregulating <italic>Alk3</italic> activity (that is, overexpressing truncated <italic>Alk3</italic>) led to decreased expression of <italic>Alp</italic> and less von Kossa staining.<sup><xref ref-type="bibr" rid="bib51">51</xref></sup> When specifically deleting <italic>Alk3</italic> in the early development of the palatal mesenchyme by E12.5 using <italic>Oar2-Ires Cre</italic>, the formation of mesenchymal condensation in the palate was delayed as was the consequent palate bone formation.<sup><xref ref-type="bibr" rid="bib56">56</xref></sup> This <italic>in vivo</italic> study, together with the <italic>in vitro</italic> study, suggested that ALK3-induced BMP signaling was required for the differentiation of MSCs toward the osteolineage. However, other groups came to an opposite conclusion in similar studies. The downregulation of <italic>Alk3</italic> in 2T3 cells (characterized as osteoblast precursors) or the conditional deletion of <italic>Alk3</italic> in bone marrow mesenchymal cells using <italic>Mx1 Cre</italic> (Cre is activated in an osteolineage-restricted stem/progenitor cell subset, one specific subset of bone marrow mesenchymal cells<sup><xref ref-type="bibr" rid="bib57">57</xref></sup>) led to ectopic mineralization via the upregulation of the bone formation activity of osteoblasts,<sup><xref ref-type="bibr" rid="bib49">49</xref>,<xref ref-type="bibr" rid="bib54">54</xref></sup> indicating that ALK3 inhibits the osteoblastic lineage commitment of bone marrow stem cells. These contrary results suggest that ALK3 may regulate (promote or inhibit) the differentiation of MSCs in a tissue-dependent manner.</p></sec><sec><title>Roles of ALK3 in osteoblasts</title><p>Deletion of <italic>Alk3</italic> specifically in immature osteoblasts using <italic>2.3&#x02009;kb Col1 Cre</italic> or <italic>3.2&#x02009;kb Col1 Cre</italic> indicated that the maturation progress of these osteoblasts was suppressed because both the bone formation rate and the mineral apposition rate were downregulated.<sup><xref ref-type="bibr" rid="bib58 bib59 bib60">58&#x02013;60</xref></sup> An analysis of these mutant osteoblasts found an enhanced proliferation with decreased expression of several specific osteoblast markers, including <italic>Runx2, Osx, bone sialoprotein</italic> (<italic>Bsp</italic>), and <italic>Alp</italic>.<sup><xref ref-type="bibr" rid="bib58 bib59 bib60">58&#x02013;60</xref></sup> Mice with a specific disruption of <italic>Alk3</italic> in differentiated osteoblasts (using <italic>Og2 Cre</italic>) were born normally and did not exhibit overt bone changes, except for a slight decrease in bone mass at 3 months, which may be caused by a mild downregulation of osteoblast function (lower bone formation rate with decreased BV/TV, but no change in the expression levels of <italic>osteopontin</italic> (<italic>Opn</italic>) and <italic>Ocn</italic>),<sup><xref ref-type="bibr" rid="bib61">61</xref></sup> suggesting that ALK3 promotes mature osteoblast function and osteoblast&#x02013;osteocyte transition in a relatively mild way. However, the decreased bone mass in these mutant mice later increased and was confirmed to have an even higher bone volume compared with that of wild-type mice at 10 months, which mainly resulted from the downregulated bone resorption caused by reduced osteoclast activity.<sup><xref ref-type="bibr" rid="bib61">61</xref></sup> These results suggest that ALK3 expressed in mature osteoblasts has diverse effects on bone mass and homeostasis in an age-dependent manner.</p></sec><sec><title>Roles of ALK3 in the interaction between osteoblasts and osteoclasts</title><p>For decades, more and more studies have confirmed that there is a communication between osteoblasts and osteoclasts, which has an exquisite and important role in bone modeling and remodeling. The discoveries of the biological functions of ALK3 imply that this factor may be one of the key molecules in this process.</p><p>Osteoblasts have critical roles in bone resorption by regulating osteoclastogenesis due to their ability to produce nuclear factor kappa-B ligand (RANKL), which is essential for promoting osteoclast differentiation and function, and its decoy receptor osteoprotegerin (OPG).<sup><xref ref-type="bibr" rid="bib62">62</xref>,<xref ref-type="bibr" rid="bib63">63</xref></sup> Several studies have confirmed that ALK3-induced signaling in osteoblasts regulates osteoclastogenesis via the RANKL-OPG mechanism. The earliest direct evidence came from a report by Wan <italic>et al.</italic>,<sup><xref ref-type="bibr" rid="bib64">64</xref></sup> in which they found that the transfection of constitutively active <italic>Alk3</italic> stimulated the OPG promoter and that two homeobox C8 (Hoxc-8)-binding sites in the OPG promoter responded to the ALK3 activation. In accordance with these results, several <italic>in vivo</italic> studies have confirmed that conditional deletion of osteoblastic <italic>Alk3</italic> in distinct cell differentiation stages,<sup><xref ref-type="bibr" rid="bib59">59</xref>,<xref ref-type="bibr" rid="bib60">60</xref>,<xref ref-type="bibr" rid="bib61">61</xref></sup> or in different developmental periods,<sup><xref ref-type="bibr" rid="bib58">58</xref>,<xref ref-type="bibr" rid="bib60">60</xref>,<xref ref-type="bibr" rid="bib61">61</xref>,<xref ref-type="bibr" rid="bib65">65</xref></sup> led to decreased osteoclast numbers and decreased expression of bone resorption markers (<italic>matrix metallopeptidase 9</italic> (<italic>Mmp9</italic>), <italic>tartrate-resistant acid phosphatase</italic> (<italic>Trap</italic>), and <italic>cathepsin K</italic> (<italic>CatK</italic>), among others). Furthermore, accumulating evidence suggests that crosstalk between BMP and Wnt signaling in bone may also be involved in osteoblast-regulated osteoclastogenesis through the RANKL-OPG pathway. Kamiya <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib60">60</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="bib65">65</xref></sup> recognized that a disruption of ALK3-induced signaling, including both Smad and non-Smad signaling (such as p38 MAPK), in osteoblasts resulted in upregulated Wnt/&#x003b2;-catenin activity due to decreased production of its downstream targets, DKK1 and SOST.<sup><xref ref-type="bibr" rid="bib60">60</xref>,<xref ref-type="bibr" rid="bib65">65</xref></sup> It is widely reported that canonical Wnt signaling in osteoblasts negatively regulates their supporting function in osteoclastogenesis by affecting RANKL and OPG expression, thus inhibiting osteoclast differentiation and activity as well as suppressing osteoclast-mediated bone resorption.<sup><xref ref-type="bibr" rid="bib66">66</xref>,<xref ref-type="bibr" rid="bib67">67</xref></sup> Taken together, in osteoblasts, ALK3 activates SOST and DKK1, while both SOST and DKK1 inhibit canonical Wnt signaling and maintain the activity of Wnt/&#x003b2;-catenin signaling at a certain level.<sup><xref ref-type="bibr" rid="bib68 bib69 bib70 bib71">68&#x02013;71</xref></sup> As a result, ALK3-induced BMP signaling and Wnt signaling contribute not only to osteoblast proliferation, differentiation, and maturation, but also to the regulation of osteoclastogenesis (mainly via the RANKL-OPG pathway; <xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>However, ALK3 signaling in osteoclasts also negatively regulates osteoblast functions. For example, conditionally disturbed <italic>Alk3</italic> expression in osteoclasts using <italic>CatK Cre</italic> not only inhibited osteoclast function but also enhanced osteoblast function, that is, increased osteoblast number and bone formation rate.<sup><xref ref-type="bibr" rid="bib59">59</xref></sup> Furthermore, it has been reported that several factors (including platelet-derived growth factor BB, v-ATPase V0 subunit d2 (Atp6v0d2), CatK and osteoclast inhibitory lectin (OCIL)) produced by osteoclasts negatively affect osteoblast functions.<sup><xref ref-type="bibr" rid="bib72 bib73 bib74 bib75">72&#x02013;75</xref></sup> Among these osteoclast-derived osteoblastic inhibitors, both CatK and ATV6v0d2 were significantly increased after a stimulation of Smad-dependent ALK3 signaling in osteoclasts.<sup><xref ref-type="bibr" rid="bib76 bib77 bib78">76&#x02013;78</xref></sup> Collectively, BMPs might bind to ALK3 on the surface of osteoclasts and activate BMP signaling, leading to the upregulation of factors such as CatK and ATV6v0d2, which suppress osteoblast activity and downregulate the rate of bone formation.<sup><xref ref-type="bibr" rid="bib76">76</xref>,<xref ref-type="bibr" rid="bib77">77</xref>,<xref ref-type="bibr" rid="bib79">79</xref></sup></p></sec><sec><title>Roles of ALK3 in chondrogenesis</title><p>Although ALK3 mainly functions in osteogenesis, it also has an important role in chondrogenesis. For instance, a forced expression of <italic>Alk3</italic> in MSCs (C3H10T1/2)<sup><xref ref-type="bibr" rid="bib51">51</xref></sup> or pre-chondrocytes<sup><xref ref-type="bibr" rid="bib80">80</xref></sup> induced chondrogenic differentiation, while downregulated <italic>Alk3</italic> suppressed this process.<sup><xref ref-type="bibr" rid="bib51">51</xref></sup> The regulatory function of ALK3 in chondrogenesis has been further supported by <italic>in vivo</italic> studies.<sup><xref ref-type="bibr" rid="bib81 bib82 bib83 bib84 bib85 bib86">81&#x02013;86</xref></sup> Initially, the role of ALK3 in chondrogenesis, such as regulating chondrocyte proliferation, survival, and differentiation, was thought to be associated with ALK6 during chondrogenesis.<sup><xref ref-type="bibr" rid="bib81">81</xref></sup> Soon after, it was demonstrated that ALK3 itself has a unique and broad role during chondrogenesis. First, overexpressing a constitutively active ALK3 in chondrocytes <italic>in vivo</italic> stimulated the differentiation of pre-chondrocytes and proliferating chondrocytes, promoting their maturation toward hypertrophy.<sup><xref ref-type="bibr" rid="bib82">82</xref></sup> Second, the conditional deletion of <italic>Alk3</italic> specifically in developing joints resulted in the downregulation of proteoglycans and extracellular matrix cartilage genes, including <italic>Col2</italic>, <italic>Col10</italic>, and <italic>Agg</italic>, leading to articular cartilage fibrosis and degeneration during postnatal development.<sup><xref ref-type="bibr" rid="bib83">83</xref></sup> Third, <italic>Alk3</italic> ablation in postnatal chondrocytes caused arrested chondrogenesis and endochondral ossification, with diminished chondrocyte proliferation and little expression of cartilage markers, such as SOX9, Indian hedgehog, Col II, Col X, AGG, and glycoproteins, among others.<sup><xref ref-type="bibr" rid="bib84 bib85 bib86">84&#x02013;86</xref></sup> Taken together, these studies support the notion that ALK3 is one of the key factors for regulating the specification of pre-chondrogenic mesenchyme as well as chondrolineage differentiation and maturation, postnatal chondrogenesis and the maintenance of articular cartilage.</p></sec></sec><sec><title>Biological functions of ALK6 in bone formation</title><p>The expression of ALK6 is primarily restricted to mesenchymal pre-cartilage condensations during mouse development, but it has also been identified in differentiated chondrocytes and osteoblasts in adult mice.<sup><xref ref-type="bibr" rid="bib50">50</xref>,<xref ref-type="bibr" rid="bib87 bib88 bib89">87&#x02013;89</xref></sup> Accordingly, a study of different cell lines suggested that <italic>Alk6</italic> was expressed at a low level or was undetectable in MSCs; however, it was specifically upregulated during osteoblastic differentiation.<sup><xref ref-type="bibr" rid="bib14">14</xref>,<xref ref-type="bibr" rid="bib51">51</xref>,<xref ref-type="bibr" rid="bib53">53</xref></sup> These ALK6 expression patterns suggest that it may participate in chondrogenesis and influence late osteolineage cells.</p><sec><title>ALK6 in regulating chondrogenesis</title><p>Patients with a homozygous mutation in <italic>ALK6</italic> have severe limb deformations consisting of a short stature, aplasia of the fibula, severe brachydactyly and ulnar deviation of the hands, which mainly result from chondrodysplasia during skeletal development.<sup><xref ref-type="bibr" rid="bib90">90</xref></sup> In addition, constitutive expression of <italic>Alk6</italic> in pre-chondrocytes significantly increases the induction of chondrocyte differentiation.<sup><xref ref-type="bibr" rid="bib80">80</xref>,<xref ref-type="bibr" rid="bib91">91</xref></sup> Accordingly, several <italic>in vivo</italic> studies have consistently demonstrated that ALK6 is required for the proliferation and chondrogenic differentiation of pre-chondrogenic and proliferating chondrocytes.<sup><xref ref-type="bibr" rid="bib82">82</xref>,<xref ref-type="bibr" rid="bib88">88</xref></sup> However, null mutations of <italic>Alk6</italic> only exhibited mild limb abnormalities that were largely restricted to the appendicular skeleton.<sup><xref ref-type="bibr" rid="bib82">82</xref>,<xref ref-type="bibr" rid="bib88">88</xref>,<xref ref-type="bibr" rid="bib92">92</xref></sup> Soyun Yi<sup><xref ref-type="bibr" rid="bib88">88</xref></sup> posited that ALK6 had broadly overlapping functions with other BMP receptors because a <italic>Alk6</italic>-<italic>Bmp7</italic> double-mutant exhibited more-severe skeletal defects than did an <italic>Alk6</italic> single-knockout. Later, it was suggested that ALK3 and ALK6 display functionally redundant aspects during early chondrogenesis<sup><xref ref-type="bibr" rid="bib81">81</xref></sup> because ALK6 signaling could be replaced by constitutively active ALK3.<sup><xref ref-type="bibr" rid="bib82">82</xref></sup> In summary, these results indicate that ALK6, rather than having a unique role, may have overlapping functions with other BMP receptors, especially ALK3, in supporting pre-chondrogenic mesenchyme as well as chondrocyte proliferation, differentiation, and maturation.</p></sec><sec><title>ALK6 in regulating osteogenesis</title><p><italic>In vitro</italic> studies have found that the expression of a constitutively active <italic>Alk6</italic> induced the formation of mineralized bone matrix, while the overexpression of truncated <italic>Alk6</italic> or the inhibition of endogenous <italic>Alk6</italic> completely blocked BMP2-induced osteoblast differentiation and mineralized bone matrix formation.<sup><xref ref-type="bibr" rid="bib54">54</xref></sup> These results suggest that the osteoblastic ALK6 is required for osteoblast differentiation and bone formation. Transgenic mice that expressed a truncated dominant-negative <italic>Alk6</italic> in targeted osteoblasts using the <italic>2.3&#x02009;kb Col1</italic> promoter exhibited impaired postnatal bone formation, including severely reduced bone mineral density, bone volume, and bone formation rates. These characteristics indicate that the osteoblastic ALK6 has a necessary role during postnatal bone modeling and remodeling via regulating osteoblast/osteocyte maturation.<sup><xref ref-type="bibr" rid="bib93">93</xref></sup> However, in <italic>Alk6</italic> null mice, the defects largely resulted from the disturbed chondrogenesis, and there was little influence on osteogenesis,<sup><xref ref-type="bibr" rid="bib88">88</xref></sup> implying that the regulatory role of ALK6 is mildly involved in bone ossification.</p></sec></sec><sec><title>Conclusion</title><p>In conclusion, all three types of BMPRI have distinct but important roles during chondrogenesis, osteogenesis, and osteoclastogenesis. They might not only directly regulate the chondrogenic or osteogenic differentiation of bone cells and influence osteoclast activity through the RANKL-OPG pathway but also crosstalk with Wnt signaling by altering their downstream molecules, including DKK1 and SOST, during bone development and homeostasis. Despite some knowledge gaps, much has been learned over recent decades about the functions of BMPRI in a variety of cell types, including MSCs, chondrocytes, osteoblasts, osteoclasts, and myoblasts, using genetic animal models. However, its regulatory role in osteocytes remains unknown. Although osteocytes, which compose 90%&#x02013;95% of all bone cells in adult bone, have recently been demonstrated to be crucial for bone biology because of their functions in inducing osteoclasts, regulating mineral metabolism and matrix remodeling, and reacting to mechanical loading.<sup><xref ref-type="bibr" rid="bib94">94</xref></sup> Furthermore, studies of BMPRI have been fueled by the desire to understand the molecular underpinnings of rare bone diseases or the mechanisms of clinical applications for BMPs in common diseases, such as bone fracture healing and spinal surgery, and these studies now might contribute to the development of new therapies for congenital or age-related bone diseases. Recently, Marc Baud&#x02019;huin <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib95">95</xref></sup> developed a soluble mBMPRIA (ALK3)-mFc fusion protein and found that mBMPRIA (ALK3)-mFc treatment could successfully downregulate Smad-dependent ALK3 signaling, thus increasing bone mass in both young (7&#x02013;10 weeks) and old (14&#x02013;18 weeks) mice or preventing bone loss induced by estrogen deficiency in ovariectomized mice. This work set an example showing that regulation of signaling through BMPRI may have therapeutic benefits. Hence, continuing the bedside-to-bench exchange of information about BMPRI will help to provide novel, therapeutically useful strategies for skeletal physiology, pathology, and regeneration.</p></sec></body><back><ack><p>This work was supported by the National Natural Science Foundation of China (No. 81500814) (SXL); the National Basic Research Program of China (973 Program, 2012CB933604), the National Science Fund for Distinguished Young Scholars of China (No. 81225006) and the National Natural Science Foundation of China (No. 81430012 and No. 81170939) (XJ); and the National Institutes of Health Grants DE025014 and R56DE022789 (JQF). We would like to thank Jeanne Santa Cruz for her assistance in preparing the manuscript.</p></ack><notes><p>The authors declare no conflict of interest.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal">Wozney JM. <article-title>Bone morphogenetic proteins</article-title>. <source>Prog Growth Factor Res</source>
<year>1989</year>; <volume>1</volume>: <fpage>267</fpage>&#x02013;280.<pub-id pub-id-type="pmid">2491264</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal">Urist MR. <article-title>Bone: formation by autoinduction</article-title>. <source>Science</source>
<year>1965</year>; <volume>150</volume>: <fpage>893</fpage>&#x02013;899.<pub-id pub-id-type="pmid">5319761</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal">Chen D, Zhao M, Mundy GR. <article-title>Bone morphogenetic proteins</article-title>. <source>Growth Factors</source>
<year>2004</year>; <volume>22</volume>: <fpage>233</fpage>&#x02013;241.<pub-id pub-id-type="pmid">15621726</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal">Kang Q, Sun MH, Cheng H et al. <article-title>Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery</article-title>. <source>Gene Ther</source>
<year>2004</year>; <volume>11</volume>: <fpage>1312</fpage>&#x02013;1320.<pub-id pub-id-type="pmid">15269709</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal">Gautschi OP, Frey SP, Zellweger R. <article-title>Bone morphogenetic proteins in clinical applications</article-title>. <source>ANZ J Surg</source>
<year>2007</year>; <volume>77</volume>: <fpage>626</fpage>&#x02013;631.<pub-id pub-id-type="pmid">17635273</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal">Koenig BB, Cook JS, Wolsing DH et al. <article-title>Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells</article-title>. <source>Mol Cell Biol</source>
<year>1994</year>; <volume>14</volume>: <fpage>5961</fpage>&#x02013;5974.<pub-id pub-id-type="pmid">8065329</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal">Hoodless PA, Haerry T, Abdollah S et al. <article-title>MADR1, a MAD-related protein that functions in BMP2 signaling pathways</article-title>. <source>Cell</source>
<year>1996</year>; <volume>85</volume>: <fpage>489</fpage>&#x02013;500.<pub-id pub-id-type="pmid">8653785</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal">Chen Y, Bhushan A, Vale W. <article-title>Smad8 mediates the signaling of the ALK-2 [corrected] receptor serine kinase</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>1997</year>; <volume>94</volume>: <fpage>12938</fpage>&#x02013;12943.<pub-id pub-id-type="pmid">9371779</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal">Nishimura R, Kato Y, Chen D et al. <article-title>Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12</article-title>. <source>J Biol Chem</source>
<year>1998</year>; <volume>273</volume>: <fpage>1872</fpage>&#x02013;1879.<pub-id pub-id-type="pmid">9442019</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal">Hauburger A, von Einem S, Schwaerzer GK et al. <article-title>The pro-form of BMP-2 interferes with BMP-2 signalling by competing with BMP-2 for IA receptor binding</article-title>. <source>FEBS J</source>
<year>2009</year>; <volume>276</volume>: <fpage>6386</fpage>&#x02013;6398.<pub-id pub-id-type="pmid">19804412</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal">ten Dijke P, Yamashita H, Sampath TK et al. <article-title>Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4</article-title>. <source>J Biol Chem</source>
<year>1994</year>; <volume>269</volume>: <fpage>16985</fpage>&#x02013;16988.<pub-id pub-id-type="pmid">8006002</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal">Cheifetz S. <article-title>BMP receptors in limb and tooth formation</article-title>. <source>Crit Rev Oral Biol Med</source>
<year>1999</year>; <volume>10</volume>: <fpage>182</fpage>&#x02013;198.<pub-id pub-id-type="pmid">10759421</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal">Kamiya N, Kaartinen VM, Mishina Y. <article-title>Loss-of-function of ACVR1 in osteoblasts increases bone mass and activates canonical Wnt signaling through suppression of Wnt inhibitors SOST and DKK1</article-title>. <source>Biochem Biophys Res Commun</source>
<year>2011</year>; <volume>414</volume>: <fpage>326</fpage>&#x02013;330.<pub-id pub-id-type="pmid">21945937</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal">Lavery K, Swain P, Falb D, Alaoui-Ismaili MH. <article-title>BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells</article-title>. <source>J Biol Chem</source>
<year>2008</year>; <volume>283</volume>: <fpage>20948</fpage>&#x02013;20958.<pub-id pub-id-type="pmid">18436533</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal">Shore EM, Xu M, Feldman GJ et al. <article-title>A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva</article-title>. <source>Nat Genet</source>
<year>2006</year>; <volume>38</volume>: <fpage>525</fpage>&#x02013;527.<pub-id pub-id-type="pmid">16642017</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal">Huning I, Gillessen-Kaesbach G. <article-title>Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation</article-title>. <source>Mol Syndromol</source>
<year>2014</year>; <volume>5</volume>: <fpage>201</fpage>&#x02013;211.<pub-id pub-id-type="pmid">25337067</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal">Zhang W, Zhang K, Song L et al. <article-title>The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases</article-title>. <source>Bone</source>
<year>2013</year>; <volume>57</volume>: <fpage>386</fpage>&#x02013;391.<pub-id pub-id-type="pmid">24051199</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal">Carvalho DR, Navarro MM, Martins BJ et al. <article-title>Mutational screening of ACVR1 gene in Brazilian fibrodysplasia ossificans progressiva patients</article-title>. <source>Clin Genet</source>
<year>2010</year>; <volume>77</volume>: <fpage>171</fpage>&#x02013;176.<pub-id pub-id-type="pmid">19796185</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal">Kaplan FS, Xu M, Seemann P et al. <article-title>Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1</article-title>. <source>Hum Mutat</source>
<year>2009</year>; <volume>30</volume>: <fpage>379</fpage>&#x02013;390.<pub-id pub-id-type="pmid">19085907</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal">Nakajima M, Haga N, Takikawa K et al. <article-title>The ACVR1 617G&#x0003e;A mutation is also recurrent in three Japanese patients with fibrodysplasia ossificans progressiva</article-title>. <source>J Hum Genet</source>
<year>2007</year>; <volume>52</volume>: <fpage>473</fpage>&#x02013;475.<pub-id pub-id-type="pmid">17351709</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal">Al-Haggar M, Ahmad N, Yahia S et al. <article-title>Sporadic fibrodysplasia ossificans progressiva in an Egyptian infant with c.617G&#x0003e;A mutation in ACVR1 gene: a case report and review of literature</article-title>. <source>Case Rep Genet</source>
<year>2013</year>; <volume>2013</volume>: <fpage>834605</fpage>.<pub-id pub-id-type="pmid">23424689</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal">Furuya H, Ikezoe K, Wang L et al. <article-title>A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H)</article-title>. <source>Am J Med Genet A</source>
<year>2008</year>; <volume>146</volume>: <fpage>459</fpage>&#x02013;463.</mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal">Cohen RB, Hahn GV, Tabas JA et al. <article-title>The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients</article-title>. <source>J Bone Joint Surg Am</source>
<year>1993</year>; <volume>75</volume>: <fpage>215</fpage>&#x02013;219.<pub-id pub-id-type="pmid">8423182</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal">Connor JM, Evans DA. <article-title>Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients</article-title>. <source>J Bone Joint Surg Br</source>
<year>1982</year>; <volume>64</volume>: <fpage>76</fpage>&#x02013;83.<pub-id pub-id-type="pmid">7068725</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal">Virdi AS, Shore EM, Oreffo RO et al. <article-title>Phenotypic and molecular heterogeneity in fibrodysplasia ossificans progressiva</article-title>. <source>Calcif Tissue Int</source>
<year>1999</year>; <volume>65</volume>: <fpage>250</fpage>&#x02013;255.<pub-id pub-id-type="pmid">10441661</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal">Bocciardi R, Bordo D, Di Duca M et al. <article-title>Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements</article-title>. <source>Eur J Hum Genet</source>
<year>2009</year>; <volume>17</volume>: <fpage>311</fpage>&#x02013;318.<pub-id pub-id-type="pmid">18830232</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal">Ratbi I, Borcciadi R, Regragui A et al. <article-title>Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva</article-title>. <source>Clin Rheumatol</source>
<year>2010</year>; <volume>29</volume>: <fpage>119</fpage>&#x02013;121.<pub-id pub-id-type="pmid">19795179</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal">Morales-Piga A, Bachiller-Corral J, Trujillo-Tiebas MJ et al. <article-title>Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects</article-title>. <source>Bone</source>
<year>2012</year>; <volume>51</volume>: <fpage>748</fpage>&#x02013;755.<pub-id pub-id-type="pmid">22796417</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal">Gregson CL, Hollingworth P, Williams M et al. <article-title>A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date</article-title>. <source>Bone</source>
<year>2011</year>; <volume>48</volume>: <fpage>654</fpage>&#x02013;658.<pub-id pub-id-type="pmid">21044902</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal">Nakahara Y, Katagiri T, Ogata N et al. <article-title>ACVR1 (587T&#x0003e;C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report</article-title>. <source>Am J Med Genet A</source>
<year>2014</year>; <volume>164</volume>: <fpage>220</fpage>&#x02013;224.</mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal">Petrie KA, Lee WH, Bullock AN et al. <article-title>Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients</article-title>. <source>PLoS One</source>
<year>2009</year>; <volume>4</volume>: <fpage>e5005</fpage>.<pub-id pub-id-type="pmid">19330033</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal">Yu PB, Deng DY, Lai CS et al. <article-title>BMP type I receptor inhibition reduces heterotopic [corrected] ossification</article-title>. <source>Nat Med</source>
<year>2008</year>; <volume>14</volume>: <fpage>1363</fpage>&#x02013;1369.<pub-id pub-id-type="pmid">19029982</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal">Chakkalakal SA, Zhang D, Culbert AL et al. <article-title>An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva</article-title>. <source>J Bone Miner Res</source>
<year>2012</year>; <volume>27</volume>: <fpage>1746</fpage>&#x02013;1756.<pub-id pub-id-type="pmid">22508565</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal">Takahashi M, Katagiri T, Furuya H et al. <article-title>Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva</article-title>. <source>Gene Ther</source>
<year>2012</year>; <volume>19</volume>: <fpage>781</fpage>&#x02013;785.<pub-id pub-id-type="pmid">22130450</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal">Fukuda T, Kanomata K, Nojima J et al. <article-title>A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor</article-title>. <source>Biochem Biophys Res Commun</source>
<year>2008</year>; <volume>377</volume>: <fpage>905</fpage>&#x02013;909.<pub-id pub-id-type="pmid">18952055</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal">Shen Q, Little SC, Xu M et al. <article-title>The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization</article-title>. <source>J Clin Invest</source>
<year>2009</year>; <volume>119</volume>: <fpage>3462</fpage>&#x02013;3472.<pub-id pub-id-type="pmid">19855136</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal">Ohte S, Shin M, Sasanuma H et al. <article-title>A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H</article-title>. <source>Biochem Biophys Res Commun</source>
<year>2011</year>; <volume>407</volume>: <fpage>213</fpage>&#x02013;218.<pub-id pub-id-type="pmid">21377447</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal">Wieser R, Wrana JL, Massague J. <article-title>GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex</article-title>. <source>EMBO J</source>
<year>1995</year>; <volume>14</volume>: <fpage>2199</fpage>&#x02013;2208.<pub-id pub-id-type="pmid">7774578</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal">Culbert AL, Chakkalakal SA, Theosmy EG et al. <article-title>Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification</article-title>. <source>Stem Cells</source>
<year>2014</year>; <volume>32</volume>: <fpage>1289</fpage>&#x02013;1300.<pub-id pub-id-type="pmid">24449086</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal">Yano M, Kawao N, Tamura Y et al. <article-title>A novel factor, Tmem176b, induced by activin-like kinase 2 signal promotes the differentiation of myoblasts into osteoblasts</article-title>. <source>Exp Clin Endocrinol Diabetes</source>
<year>2014</year>; <volume>122</volume>: <fpage>7</fpage>&#x02013;14.<pub-id pub-id-type="pmid">24085390</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal">van Dinther M, Visser N, de Gorter DJ et al. <article-title>ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation</article-title>. <source>J Bone Miner Res</source>
<year>2010</year>; <volume>25</volume>: <fpage>1208</fpage>&#x02013;1215.<pub-id pub-id-type="pmid">19929436</pub-id></mixed-citation></ref><ref id="bib42"><mixed-citation publication-type="journal">Shi S, Cai J, de Gorter DJ et al. <article-title>Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva</article-title>. <source>PLoS One</source>
<year>2013</year>; <volume>8</volume>: <fpage>e69096</fpage>.<pub-id pub-id-type="pmid">23861958</pub-id></mixed-citation></ref><ref id="bib43"><mixed-citation publication-type="journal">Kaplan J, Kaplan FS, Shore EM. <article-title>Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting</article-title>. <source>Gene Ther</source>
<year>2012</year>; <volume>19</volume>: <fpage>786</fpage>&#x02013;790.<pub-id pub-id-type="pmid">22011642</pub-id></mixed-citation></ref><ref id="bib44"><mixed-citation publication-type="journal">Agarwal S, Loder SJ, Brownley C et al. <article-title>BMP signaling mediated by constitutively active Activin type 1 receptor (ACVR1) results in ectopic bone formation localized to distal extremity joints</article-title>. <source>Dev Biol</source>
<year>2015</year>; <volume>400</volume>: <fpage>202</fpage>&#x02013;209.<pub-id pub-id-type="pmid">25722188</pub-id></mixed-citation></ref><ref id="bib45"><mixed-citation publication-type="journal">Zhang D, Schwarz EM, Rosier RN et al. <article-title>ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development</article-title>. <source>J Bone Miner Res</source>
<year>2003</year>; <volume>18</volume>: <fpage>1593</fpage>&#x02013;1604.<pub-id pub-id-type="pmid">12968668</pub-id></mixed-citation></ref><ref id="bib46"><mixed-citation publication-type="journal">Liu F, Kohlmeier S, Wang CY. <article-title>Wnt signaling and skeletal development</article-title>. <source>Cell Signal</source>
<year>2008</year>; <volume>20</volume>: <fpage>999</fpage>&#x02013;1009.<pub-id pub-id-type="pmid">18164181</pub-id></mixed-citation></ref><ref id="bib47"><mixed-citation publication-type="journal">Yano M, Kawao N, Okumoto K et al. <article-title>Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues</article-title>. <source>J Biol Chem</source>
<year>2014</year>; <volume>289</volume>: <fpage>16966</fpage>&#x02013;16977.<pub-id pub-id-type="pmid">24798338</pub-id></mixed-citation></ref><ref id="bib48"><mixed-citation publication-type="other">Kawao N, Yano M, Tamura Y et al. <article-title>Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice</article-title>. <source>J Bone Miner Metab</source>
<year>2015</year>. [E-pub ahead of print].</mixed-citation></ref><ref id="bib49"><mixed-citation publication-type="journal">Zhang J, Niu C, Ye L et al. <article-title>Identification of the haematopoietic stem cell niche and control of the niche size</article-title>. <source>Nature</source>
<year>2003</year>; <volume>425</volume>: <fpage>836</fpage>&#x02013;841.<pub-id pub-id-type="pmid">14574412</pub-id></mixed-citation></ref><ref id="bib50"><mixed-citation publication-type="journal">Dewulf N, Verschueren K, Lonnoy O et al. <article-title>Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic proteins during mouse embryogenesis</article-title>. <source>Endocrinology</source>
<year>1995</year>; <volume>136</volume>: <fpage>2652</fpage>&#x02013;2663.<pub-id pub-id-type="pmid">7750489</pub-id></mixed-citation></ref><ref id="bib51"><mixed-citation publication-type="journal">Kaps C, Hoffmann A, Zilberman Y et al. <article-title>Distinct roles of BMP receptors Type IA and IB in osteo-/chondrogenic differentiation in mesenchymal progenitors (C3H10T1/2)</article-title>. <source>Biofactors</source>
<year>2004</year>; <volume>20</volume>: <fpage>71</fpage>&#x02013;84.<pub-id pub-id-type="pmid">15322331</pub-id></mixed-citation></ref><ref id="bib52"><mixed-citation publication-type="journal">Macias-Silva M, Hoodless PA, Tang SJ et al. <article-title>Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2</article-title>. <source>J Biol Chem</source>
<year>1998</year>; <volume>273</volume>: <fpage>25628</fpage>&#x02013;25636.<pub-id pub-id-type="pmid">9748228</pub-id></mixed-citation></ref><ref id="bib53"><mixed-citation publication-type="journal">Singhatanadgit W, Olsen I. <article-title>Endogenous BMPR-IB signaling is required for early osteoblast differentiation of human bone cells</article-title>. <source>In Vitro Cell Dev Biol Anim</source>
<year>2011</year>; <volume>47</volume>: <fpage>251</fpage>&#x02013;259.<pub-id pub-id-type="pmid">21136190</pub-id></mixed-citation></ref><ref id="bib54"><mixed-citation publication-type="journal">Chen D, Ji X, Harris MA et al. <article-title>Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages</article-title>. <source>J Cell Biol</source>
<year>1998</year>; <volume>142</volume>: <fpage>295</fpage>&#x02013;305.<pub-id pub-id-type="pmid">9660882</pub-id></mixed-citation></ref><ref id="bib55"><mixed-citation publication-type="journal">Mishina Y, Suzuki A, Ueno N et al. <article-title>Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis</article-title>. <source>Genes Dev</source>
<year>1995</year>; <volume>9</volume>: <fpage>3027</fpage>&#x02013;3037.<pub-id pub-id-type="pmid">8543149</pub-id></mixed-citation></ref><ref id="bib56"><mixed-citation publication-type="journal">Baek JA, Lan Y, Liu H et al. <article-title>Bmpr1a signaling plays critical roles in palatal shelf growth and palatal bone formation</article-title>. <source>Dev Biol</source>
<year>2011</year>; <volume>350</volume>: <fpage>520</fpage>&#x02013;531.<pub-id pub-id-type="pmid">21185278</pub-id></mixed-citation></ref><ref id="bib57"><mixed-citation publication-type="journal">Park D, Spencer JA, Koh BI et al. <article-title>Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration</article-title>. <source>Cell Stem Cell</source>
<year>2012</year>; <volume>10</volume>: <fpage>259</fpage>&#x02013;272.<pub-id pub-id-type="pmid">22385654</pub-id></mixed-citation></ref><ref id="bib58"><mixed-citation publication-type="journal">Kamiya N, Ye L, Kobayashi T et al. <article-title>Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass</article-title>. <source>J Bone Miner Res</source>
<year>2008</year>; <volume>23</volume>: <fpage>2007</fpage>&#x02013;2017.<pub-id pub-id-type="pmid">18684091</pub-id></mixed-citation></ref><ref id="bib59"><mixed-citation publication-type="journal">Okamoto M, Murai J, Imai Y et al. <article-title>Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice</article-title>. <source>J Bone Miner Res</source>
<year>2011</year>; <volume>26</volume>: <fpage>2511</fpage>&#x02013;2522.<pub-id pub-id-type="pmid">21786321</pub-id></mixed-citation></ref><ref id="bib60"><mixed-citation publication-type="journal">Kamiya N, Ye L, Kobayashi T et al. <article-title>BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway</article-title>. <source>Development</source>
<year>2008</year>; <volume>135</volume>: <fpage>3801</fpage>&#x02013;3811.<pub-id pub-id-type="pmid">18927151</pub-id></mixed-citation></ref><ref id="bib61"><mixed-citation publication-type="journal">Mishina Y, Starbuck MW, Gentile MA et al. <article-title>Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling</article-title>. <source>J Biol Chem</source>
<year>2004</year>; <volume>279</volume>: <fpage>27560</fpage>&#x02013;27566.<pub-id pub-id-type="pmid">15090551</pub-id></mixed-citation></ref><ref id="bib62"><mixed-citation publication-type="journal">Simonet WS, Lacey DL, Dunstan CR et al. <article-title>Osteoprotegerin: a novel secreted protein involved in the regulation of bone density</article-title>. <source>Cell</source>
<year>1997</year>; <volume>89</volume>: <fpage>309</fpage>&#x02013;319.<pub-id pub-id-type="pmid">9108485</pub-id></mixed-citation></ref><ref id="bib63"><mixed-citation publication-type="journal">Lacey DL, Timms E, Tan HL et al. <article-title>Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation</article-title>. <source>Cell</source>
<year>1998</year>; <volume>93</volume>: <fpage>165</fpage>&#x02013;176.<pub-id pub-id-type="pmid">9568710</pub-id></mixed-citation></ref><ref id="bib64"><mixed-citation publication-type="journal">Wan M, Shi X, Feng X et al. <article-title>Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression</article-title>. <source>J Biol Chem</source>
<year>2001</year>; <volume>276</volume>: <fpage>10119</fpage>&#x02013;10125.<pub-id pub-id-type="pmid">11139569</pub-id></mixed-citation></ref><ref id="bib65"><mixed-citation publication-type="journal">Kamiya N, Kobayashi T, Mochida Y et al. <article-title>Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts</article-title>. <source>J Bone Miner Res</source>
<year>2010</year>; <volume>25</volume>: <fpage>200</fpage>&#x02013;210.<pub-id pub-id-type="pmid">19874086</pub-id></mixed-citation></ref><ref id="bib66"><mixed-citation publication-type="journal">Glass DA 2nd, Bialek P, Ahn JD et al. <article-title>Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation</article-title>. <source>Dev Cell</source>
<year>2005</year>; <volume>8</volume>: <fpage>751</fpage>&#x02013;764.<pub-id pub-id-type="pmid">15866165</pub-id></mixed-citation></ref><ref id="bib67"><mixed-citation publication-type="journal">Holmen SL, Zylstra CR, Mukherjee A et al. <article-title>Essential role of beta-catenin in postnatal bone acquisition</article-title>. <source>J Biol Chem</source>
<year>2005</year>; <volume>280</volume>: <fpage>21162</fpage>&#x02013;21168.<pub-id pub-id-type="pmid">15802266</pub-id></mixed-citation></ref><ref id="bib68"><mixed-citation publication-type="journal">Moester MJ, Papapoulos SE, Lowik CW et al. <article-title>Sclerostin: current knowledge and future perspectives</article-title>. <source>Calcif Tissue Int</source>
<year>2010</year>; <volume>87</volume>: <fpage>99</fpage>&#x02013;107.<pub-id pub-id-type="pmid">20473488</pub-id></mixed-citation></ref><ref id="bib69"><mixed-citation publication-type="journal">van Bezooijen RL, Roelen BA, Visser A et al. <article-title>Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist</article-title>. <source>J Exp Med</source>
<year>2004</year>; <volume>199</volume>: <fpage>805</fpage>&#x02013;814.<pub-id pub-id-type="pmid">15024046</pub-id></mixed-citation></ref><ref id="bib70"><mixed-citation publication-type="journal">MacDonald BT, Joiner DM, Oyserman SM et al. <article-title>Bone mass is inversely proportional to Dkk1 levels in mice</article-title>. <source>Bone</source>
<year>2007</year>; <volume>41</volume>: <fpage>331</fpage>&#x02013;339.<pub-id pub-id-type="pmid">17613296</pub-id></mixed-citation></ref><ref id="bib71"><mixed-citation publication-type="journal">Monroe DG, McGee-Lawrence ME, Oursler MJ et al. <article-title>Update on Wnt signaling in bone cell biology and bone disease</article-title>. <source>Gene</source>
<year>2012</year>; <volume>492</volume>: <fpage>1</fpage>&#x02013;18.<pub-id pub-id-type="pmid">22079544</pub-id></mixed-citation></ref><ref id="bib72"><mixed-citation publication-type="journal">Kubota K, Sakikawa C, Katsumata M et al. <article-title>Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor</article-title>. <source>J Bone Miner Res</source>
<year>2002</year>; <volume>17</volume>: <fpage>257</fpage>&#x02013;265.<pub-id pub-id-type="pmid">11811556</pub-id></mixed-citation></ref><ref id="bib73"><mixed-citation publication-type="journal">Lee SH, Rho J, Jeong D et al. <article-title>v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation</article-title>. <source>Nat Med</source>
<year>2006</year>; <volume>12</volume>: <fpage>1403</fpage>&#x02013;1409.<pub-id pub-id-type="pmid">17128270</pub-id></mixed-citation></ref><ref id="bib74"><mixed-citation publication-type="journal">Li CY, Jepsen KJ, Majeska RJ et al. <article-title>Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass</article-title>. <source>J Bone Miner Res</source>
<year>2006</year>; <volume>21</volume>: <fpage>865</fpage>&#x02013;875.<pub-id pub-id-type="pmid">16753017</pub-id></mixed-citation></ref><ref id="bib75"><mixed-citation publication-type="journal">Nakamura A, Ly C, Cipetic M et al. <article-title>Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function <italic>in vitro</italic></article-title>. <source>Bone</source>
<year>2007</year>; <volume>40</volume>: <fpage>305</fpage>&#x02013;315.<pub-id pub-id-type="pmid">17049328</pub-id></mixed-citation></ref><ref id="bib76"><mixed-citation publication-type="journal">Kaneko H, Arakawa T, Mano H et al. <article-title>Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts</article-title>. <source>Bone</source>
<year>2000</year>; <volume>27</volume>: <fpage>479</fpage>&#x02013;486.<pub-id pub-id-type="pmid">11033442</pub-id></mixed-citation></ref><ref id="bib77"><mixed-citation publication-type="journal">Itoh K, Udagawa N, Katagiri T et al. <article-title>Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand</article-title>. <source>Endocrinology</source>
<year>2001</year>; <volume>142</volume>: <fpage>3656</fpage>&#x02013;3662.<pub-id pub-id-type="pmid">11459815</pub-id></mixed-citation></ref><ref id="bib78"><mixed-citation publication-type="journal">Yamashita M, Otsuka F, Mukai T et al. <article-title>Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling</article-title>. <source>Regul Pept</source>
<year>2010</year>; <volume>162</volume>: <fpage>99</fpage>&#x02013;108.<pub-id pub-id-type="pmid">20346376</pub-id></mixed-citation></ref><ref id="bib79"><mixed-citation publication-type="journal">Jensen ED, Pham L, Billington CJ et al. <article-title>Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors</article-title>. <source>J Cell Biochem</source>
<year>2010</year>; <volume>109</volume>: <fpage>672</fpage>&#x02013;682.<pub-id pub-id-type="pmid">20039313</pub-id></mixed-citation></ref><ref id="bib80"><mixed-citation publication-type="journal">Fujii M, Takeda K, Imamura T et al. <article-title>Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation</article-title>. <source>Mol Biol Cell</source>
<year>1999</year>; <volume>10</volume>: <fpage>3801</fpage>&#x02013;3813.<pub-id pub-id-type="pmid">10564272</pub-id></mixed-citation></ref><ref id="bib81"><mixed-citation publication-type="journal">Yoon BS, Ovchinnikov DA, Yoshii I et al. <article-title>Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis <italic>in vivo</italic></article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2005</year>; <volume>102</volume>: <fpage>5062</fpage>&#x02013;5067.<pub-id pub-id-type="pmid">15781876</pub-id></mixed-citation></ref><ref id="bib82"><mixed-citation publication-type="journal">Kobayashi T, Lyons KM, McMahon AP et al. <article-title>BMP signaling stimulates cellular differentiation at multiple steps during cartilage development</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2005</year>; <volume>102</volume>: <fpage>18023</fpage>&#x02013;18027.<pub-id pub-id-type="pmid">16322106</pub-id></mixed-citation></ref><ref id="bib83"><mixed-citation publication-type="journal">Rountree RB, Schoor M, Chen H et al. <article-title>BMP receptor signaling is required for postnatal maintenance of articular cartilage</article-title>. <source>PLoS Biol</source>
<year>2004</year>; <volume>2</volume>: <fpage>e355</fpage>.<pub-id pub-id-type="pmid">15492776</pub-id></mixed-citation></ref><ref id="bib84"><mixed-citation publication-type="journal">Jing J, Ren Y, Zong Z et al. <article-title>BMP receptor 1A determines the cell fate of the postnatal growth plate</article-title>. <source>Int J Biol Sci</source>
<year>2013</year>; <volume>9</volume>: <fpage>895</fpage>&#x02013;906.<pub-id pub-id-type="pmid">24163588</pub-id></mixed-citation></ref><ref id="bib85"><mixed-citation publication-type="journal">Jing J, Hinton RJ, Feng JQ. <article-title>Bmpr1a signaling in cartilage development and endochondral bone formation</article-title>. <source>Vitam Horm</source>
<year>2015</year>; <volume>99</volume>: <fpage>273</fpage>&#x02013;291.<pub-id pub-id-type="pmid">26279380</pub-id></mixed-citation></ref><ref id="bib86"><mixed-citation publication-type="journal">Jing J, Hinton RJ, Mishina Y et al. <article-title>Critical role of Bmpr1a in mandibular condyle growth</article-title>. <source>Connect Tissue Res</source>
<year>2014</year>; <volume>55</volume>: <fpage>73</fpage>&#x02013;78.<pub-id pub-id-type="pmid">25158185</pub-id></mixed-citation></ref><ref id="bib87"><mixed-citation publication-type="journal">Ashique AM, Fu K, Richman JM. <article-title>Signalling via type IA and type IB bone morphogenetic protein receptors (BMPR) regulates intramembranous bone formation, chondrogenesis and feather formation in the chicken embryo</article-title>. <source>Int J Dev Biol</source>
<year>2002</year>; <volume>46</volume>: <fpage>243</fpage>&#x02013;253.<pub-id pub-id-type="pmid">11934153</pub-id></mixed-citation></ref><ref id="bib88"><mixed-citation publication-type="journal">Yi SE, Daluiski A, Pederson R et al. <article-title>The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb</article-title>. <source>Development</source>
<year>2000</year>; <volume>127</volume>: <fpage>621</fpage>&#x02013;630.<pub-id pub-id-type="pmid">10631182</pub-id></mixed-citation></ref><ref id="bib89"><mixed-citation publication-type="journal">Ishidou Y, Kitajima I, Obama H et al. <article-title>Enhanced expression of type I receptors for bone morphogenetic proteins during bone formation</article-title>. <source>J Bone Miner Res</source>
<year>1995</year>; <volume>10</volume>: <fpage>1651</fpage>&#x02013;1659.<pub-id pub-id-type="pmid">8592941</pub-id></mixed-citation></ref><ref id="bib90"><mixed-citation publication-type="journal">Demirhan O, Turkmen S, Schwabe GC et al. <article-title>A homozygous BMPR1B mutation causes a new subtype of acromesomelic chondrodysplasia with genital anomalies</article-title>. <source>J Med Genet</source>
<year>2005</year>; <volume>42</volume>: <fpage>314</fpage>&#x02013;317.<pub-id pub-id-type="pmid">15805157</pub-id></mixed-citation></ref><ref id="bib91"><mixed-citation publication-type="journal">Nishihara A, Fujii M, Sampath TK et al. <article-title>Bone morphogenetic protein signaling in articular chondrocyte differentiation</article-title>. <source>Biochem Biophys Res Commun</source>
<year>2003</year>; <volume>301</volume>: <fpage>617</fpage>&#x02013;622.<pub-id pub-id-type="pmid">12565908</pub-id></mixed-citation></ref><ref id="bib92"><mixed-citation publication-type="journal">Baur ST, Mai JJ, Dymecki SM. <article-title>Combinatorial signaling through BMP receptor IB and GDF5: shaping of the distal mouse limb and the genetics of distal limb diversity</article-title>. <source>Development</source>
<year>2000</year>; <volume>127</volume>: <fpage>605</fpage>&#x02013;619.<pub-id pub-id-type="pmid">10631181</pub-id></mixed-citation></ref><ref id="bib93"><mixed-citation publication-type="journal">Zhao M, Harris SE, Horn D et al. <article-title>Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation</article-title>. <source>J Cell Biol</source>
<year>2002</year>; <volume>157</volume>: <fpage>1049</fpage>&#x02013;1060.<pub-id pub-id-type="pmid">12058020</pub-id></mixed-citation></ref><ref id="bib94"><mixed-citation publication-type="journal">Bonewald LF. <article-title>The amazing osteocyte</article-title>. <source>J Bone Miner Res</source>
<year>2011</year>; <volume>26</volume>: <fpage>229</fpage>&#x02013;238.<pub-id pub-id-type="pmid">21254230</pub-id></mixed-citation></ref><ref id="bib95"><mixed-citation publication-type="journal">Baud'huin M, Solban N, Cornwall-Brady M et al. <article-title>A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2012</year>; <volume>109</volume>: <fpage>12207</fpage>&#x02013;12212.<pub-id pub-id-type="pmid">22761317</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Regulatory roles of ALK2, ALK3, and ALK6 in the various differentiation stages of osteolineage, chondrolineage, and osteoclast lineage cells and myoblasts. Osteoblasts, chondrocytes, and myoblasts are derived from mesenchymal progenitor cells, whereas osteoclasts are derived from hematopoietic precursors. BMP, bone morphogenetic protein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="boneres20165-f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>A proposed mechanism diagram describing the crosstalk between osteoblastic BMP signaling (mainly via ALK3) and canonical Wnt signaling in regulating bone homeostasis. After being activated by BMPs, the BMPRs in the cell surface induce intracellular BMP signaling, including both Smad-dependent signaling and non-Smad-dependent signaling. Then, these activated signaling pathways initiate the expression of canonical Wnt inhibitors (DKK1 and SOST), which influence the binding of Wnt ligands to their receptor complexes consisting of low-density lipoprotein (LDL) receptor-related protein 5/6 (LRP5/6) and frizzled (Fzd) receptors. As a result, cytoplasmic &#x003b2;-catenin will be degraded, and its transcriptional regulation will be diminished, resulting in a downregulation of Wnt/&#x003b2;-catenin signaling activity. The balance between BMP and canonical Wnt signaling affects bone development and homeostasis by regulating both osteogenesis and osteoclastogenesis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="boneres20165-f2"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Summary of skeletal phenotypes in mouse models with BMPRI alterations</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">Gene</th><th align="left" valign="top" charoff="50">Tg/KO/KI/CKO/CKI</th><th align="left" valign="top" charoff="50">Promoter/Cre line</th><th align="left" valign="top" charoff="50">Stage</th><th align="left" valign="top" charoff="50">BMP signal</th><th align="left" valign="top" charoff="50">Bone and cartilage phenotype(s)</th><th align="left" valign="top" charoff="50">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>ALK2</italic></td><td align="left" valign="top" charoff="50">CKI (<italic>Alk2</italic><sup><italic>Q207D</italic></sup>)</td><td align="left" valign="top" charoff="50">Ad.Cre (injection)</td><td align="left" valign="top" charoff="50">P7&#x02013;P30</td><td align="left" valign="top" charoff="50">Up</td><td align="left" valign="top" charoff="50">Heterotopic endochondral ossification</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib32">32</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKI (<italic>Alk2</italic><sup><italic>Q207D</italic></sup>)</td><td align="left" valign="top" charoff="50">CAGGS Cre<sup>ER</sup></td><td align="left" valign="top" charoff="50">P7&#x02013;P60</td><td align="left" valign="top" charoff="50">Up</td><td align="left" valign="top" charoff="50">Heterotopic endochondral ossification</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib32">32</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Het KI (<italic>Alk2</italic><sup><italic>R206H</italic></sup>)</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">6&#x02013;8 w</td><td align="left" valign="top" charoff="50">Up</td><td align="left" valign="top" charoff="50">Heterotopic endochondral ossification</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib33">33</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKO</td><td align="left" valign="top" charoff="50">3.2&#x02009;kb Col1 Cre<sup>ER</sup></td><td align="left" valign="top" charoff="50">E13.5&#x02013;E18.5, P2&#x02013;P21</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Bone mass &#x02191;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib13">13</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKI (<italic>Alk2</italic><sup><italic>R206H</italic></sup>)</td><td align="left" valign="top" charoff="50">Nfatc1 Cre</td><td align="left" valign="top" charoff="50">P4&#x02013;P40</td><td align="left" valign="top" charoff="50">Up</td><td align="left" valign="top" charoff="50">Ectopic cartilage and bone at the distal joints</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib44">44</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>ALK3</italic></td><td align="left" valign="top" charoff="50">KO</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">E7.0, E8.5</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Embryonic lethality</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib55">55</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKO</td><td align="left" valign="top" charoff="50">Oar2-Ires Cre</td><td align="left" valign="top" charoff="50">E12.5</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Palate bone formation &#x02193;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib56">56</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKO</td><td align="left" valign="top" charoff="50">Mx1 Cre<sup>PolyI:C</sup></td><td align="left" valign="top" charoff="50">Early induction: P3&#x02013;P7, Late induction: P21&#x02013;P25</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Bone mass &#x02191;, bone formation &#x02191;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib49">49</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKO</td><td align="left" valign="top" charoff="50">3.2&#x02009;kb Col1 Cre<sup>ER</sup></td><td align="left" valign="top" charoff="50">E13.5&#x02013;E18.5, P2&#x02013;P10/P14, P2&#x02013;P20/P21, 8&#x02013;10/12 w, 8&#x02013;22 w</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Bone mass &#x02191;, bone formation &#x02193;, bone resorption &#x02193;, osteoblast proliferation &#x02191;, osteoblast differentiation &#x02193;, osteoclast number &#x02193;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib58">58</xref>,<xref ref-type="bibr" rid="bib60">60</xref>,<xref ref-type="bibr" rid="bib65">65</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKO</td><td align="left" valign="top" charoff="50">2.3&#x02009;kb Col1 Cre</td><td align="left" valign="top" charoff="50">P2, 5 w, 8 w</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Bone mass &#x02191;, bone formation &#x02193;, bone resorption &#x02193;, osteoblast number &#x02191;, osteoclast number &#x02193;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib59">59</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKO</td><td align="left" valign="top" charoff="50">Og2 Cre</td><td align="left" valign="top" charoff="50">3 m, 10 m</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Bone mass (early &#x02193;, late &#x02191;), bone formation &#x02193;, bone resorption &#x02193;, osteoblast differentiation &#x02193;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib61">61</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKO</td><td align="left" valign="top" charoff="50">Ctsk Cre</td><td align="left" valign="top" charoff="50">8 w, 12 w</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Bone mass &#x02191;, bone formation &#x02191;, bone resorption &#x02193;, osteoblast number &#x02191;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib59">59</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKO</td><td align="left" valign="top" charoff="50">Col2 Cre</td><td align="left" valign="top" charoff="50">E14.5</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Generalized chondrodysplasia</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib80">80</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKO</td><td align="left" valign="top" charoff="50">Gdf5 Cre</td><td align="left" valign="top" charoff="50">1 w, 2 w, 7 w, 9 w</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Cartilage extracellular matrix &#x02193;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib83">83</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKO</td><td align="left" valign="top" charoff="50">Aggrecan Cre<sup>ER</sup></td><td align="left" valign="top" charoff="50">1 w, 2 w, 1 m, 2 m, 5 m</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Arrested endochondral bone formation, ectopic bone and fibrous formation, chondrocyte proliferation and differentiation &#x02193;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib84">84</xref>,<xref ref-type="bibr" rid="bib85">85</xref>,<xref ref-type="bibr" rid="bib86">86</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Tg (<italic>caAlk3</italic>)</td><td align="left" valign="top" charoff="50">Col2</td><td align="left" valign="top" charoff="50">E13.5, E17.5</td><td align="left" valign="top" charoff="50">Up</td><td align="left" valign="top" charoff="50">Chondrocyte maturation &#x02191;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib82">82</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">CKI (UAS-<italic>caAlk3</italic>)</td><td align="left" valign="top" charoff="50">Col2 Gal4</td><td align="left" valign="top" charoff="50">E17.5</td><td align="left" valign="top" charoff="50">Up</td><td align="left" valign="top" charoff="50">Perinatal lethality, short long bone and growth plate</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib82">82</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>ALK6</italic></td><td align="left" valign="top" charoff="50">KO</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">E12.5, E13.5, E14.5, E17.5, P0</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Restricted chondrodysplasia, chondrocyte proliferation and differentiation &#x02193;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib80">80</xref>,<xref ref-type="bibr" rid="bib82">82</xref>,<xref ref-type="bibr" rid="bib88">88</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">KO</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">E11.5, E12.5, E13.5/14, E16.5</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Restricted chondrodysplasia, mesenchymal cell proliferation and differentiation &#x02193;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib92">92</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Tg (truncated <italic>Alk6</italic>)</td><td align="left" valign="top" charoff="50">2.3&#x02009;kb Col1</td><td align="left" valign="top" charoff="50">E18.5, 1 m, 6 w, 8 w, 10 w, 12 w</td><td align="left" valign="top" charoff="50">Down</td><td align="left" valign="top" charoff="50">Bone mass &#x02193;, bone formation &#x02193;, bone mineral density &#x02193;, osteoblast number &#x02193;, osteoblast differentiation &#x02193;</td><td align="center" valign="top" charoff="50"><sup><xref ref-type="bibr" rid="bib93">93</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="t1-tfoot1"><p>BMP, bone morphogenetic protein; m, month; w, week.</p></fn></table-wrap-foot></table-wrap></floats-group></article>